EJHaem · 2026
Haploidentical Hematopoietic Stem Cell Transplantation With Anti-Thymocyte Globulin in the Treatment of Older Adults With Hematological Malignancy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kong Xin, Han Jingjing, Liu Yin, Song Baoquan, Tang Xiaowen, Xue Shengli, Miao Miao, Han Yue, Wang Ying, Chen Suning, Sun Aining, Hu Mingming, Chen Jun, Chen Feng, Zhang Jian, Qiu Hui-Ying, Wu Depei
Аннотация
OBJECTIVES: Studies on the efficacy and safety of haploidentical hematopoietic stem cell transplantation (haplo-SCT) with anti-thymocyte globulin (ATG) in patients aged ≥ 60 years remain limited.
METHODS: We performed a study presenting data from 54 patients aged ≥ 60 years with hematologic malignancies who underwent haplo-SCT with ATG.
RESULTS: The median follow-up was 15 months. The median overall survival (OS) at 1-, 2-, and 3-year was 68.4%, 51.2%, and 47.6%, respectively. The cumulative incidence of non-relapse mortality (NRM) at 1 and 3 years post haplo-SCT was 22.9% and 34.8%, respectively. The cumulative incidence of 1- and 3-years relapse rate was 11.3% and 25.6%. The 100-day cumulative incidence of Grade II-IV acute graft-versus-host disease (aGvHD) was 23.1%, while the 3-year cumulative incidence of extensive chronic graft-versus-host disease (cGvHD) was 10.4%. The absence of complete remission at the time of haplo-SCT was identified as a risk factor for OS, relapse, and NRM.
CONCLUSIONS: Our study suggests that haplo-SCT with ATG is a safe and effective treatment option for patients aged ≥ 60 years. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
METHODS: We performed a study presenting data from 54 patients aged ≥ 60 years with hematologic malignancies who underwent haplo-SCT with ATG.
RESULTS: The median follow-up was 15 months. The median overall survival (OS) at 1-, 2-, and 3-year was 68.4%, 51.2%, and 47.6%, respectively. The cumulative incidence of non-relapse mortality (NRM) at 1 and 3 years post haplo-SCT was 22.9% and 34.8%, respectively. The cumulative incidence of 1- and 3-years relapse rate was 11.3% and 25.6%. The 100-day cumulative incidence of Grade II-IV acute graft-versus-host disease (aGvHD) was 23.1%, while the 3-year cumulative incidence of extensive chronic graft-versus-host disease (cGvHD) was 10.4%. The absence of complete remission at the time of haplo-SCT was identified as a risk factor for OS, relapse, and NRM.
CONCLUSIONS: Our study suggests that haplo-SCT with ATG is a safe and effective treatment option for patients aged ≥ 60 years. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.